Compare AbbVie Inc (ABBV) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Franklin Resources, Inc. — how do they compare? AbbVie Inc trades at $254.06 (market cap $449.91B), while Franklin Resources, Inc. trades at $33.2 (market cap $17.85B). The key difference: AbbVie Inc is far larger — about 25.2× Franklin Resources, Inc.'s market cap, and Franklin Resources, Inc. pays the higher dividend (3.84%). Which is the better fit depends on your goals.
| ABBV | BEN | |
|---|---|---|
Market Cap | $449.91B | $17.85B |
Sector | Health | Financials |
52-Week High | $261.07 | $34.44 |
52-Week Low | $184.85 | $21.18 |
Enterprise Value | $513.38B | $29.68B |
Dividend Yield | 2.72% | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Franklin Resources (BEN) trades at $34.36, up 0.73% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 results expected on July 31, 2026. Revenue grew to $8.77 billion in 2025, and AUM increased to $1.79 trillion in June 2026, driven by net inflows and strategic expansions into alternatives and digital assets.
Outlook remains positive with earnings momentum and dividend yield near 4%, but risks include volatile cash flows and high P/E ratio. Analyst consensus is mixed with a $33 price target slightly below current levels, suggesting cautious optimism amid solid fundamentals and growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
